Join the Oncology Voice Network. Join for Free
What's Next: Co-creating the next reality for Field Medical after a crisis with Craig Simms
Amplify Consulting Services field medical teams pharma leadership medical value proposition biotech industry insights

What's Next: Co-creating the next reality for Field Medical after a crisis with Craig Simms


Share This Article


Summary

Today I have Craig Simms, CEO of Amplify Consulting Services and Former MSL Director of Astellas Pharma. Our topic for today is What’s Next: Co-creating the next reality for field medical teams following a global crisis. Really interesting topic, you’re going to enjoy it.

Key Points

  • What Craig is hearing from leaders in pharma, biotech, and medical device companies right now
  • Framework and powerful questions
  • Staying medically relevant, creating value, and value proposition
  • Advice to medical affair leaders in handling moral issues and getting people back to work (once the crisis is over)

Click for Source
Amplify Consulting Services, field medical teams, pharma leadership, medical value proposition, biotech industry insights

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Article
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
OVN Avatar Nidal Al-Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Explore OVN